Enchun Liu, MD
Retina Specialist · San Antonio, TXNPI 1285878983
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.3% of the total across 47 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 17.6% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for retina specialist clinicians in TX, where the typical reported total is $2,568.
Across 47 payments — averaging $53.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Apellis Pharmaceuticals, Inc.$444
- AbbVie$310
- Astellas Pharma US Inc$287
- Genentech USA, Inc.$207
- Alimera Sciences, Inc.$174
- Regeneron Healthcare Solutions, Inc.$165
- plus $932 from 10 others
Across 25 payments — averaging $3849.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$91K
- AbbVie$5K
What the payments were for
- Food & beverage$2,42796%
- Education$934%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Apellis Pharmaceuticals, Inc. | 6 | $444 |
| AbbVie(2 entities) | 8 | $310 |
| Astellas Pharma US Inc | 4 | $287 |
| Genentech USA, Inc. | 3 | $207 |
| Alimera Sciences, Inc. | 4 | $174 |
| Regeneron Healthcare Solutions, Inc. | 7 | $165 |
| Novartis | 3 | $153 |
| Mallinckrodt Enterprises LLC | 2 | $134 |
| Optovue, Inc. | 1 | $120 |
| Sun Pharmaceutical Industries Inc. | 1 | $104 |
| Aerie Pharmaceuticals, Inc. | 1 | $98 |
| Mallinckrodt Hospital Products Inc. | 1 | $93 |
| Bausch & Lomb Americas Inc. | 1 | $89 |
| Alcon | 2 | $60 |
| ANI Pharmaceuticals, Inc. | 2 | $42 |
| Harrow Eye, LLC | 1 | $38 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,520 in reported general payments places this provider in the 45th percentile of 108 retina specialist providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CombiganBrimonidine Tartrate/Timolol | 30 | $8,298 |
| LumiganBimatoprost | 23 | $6,895 |
| RestasisCyclosporine | 12 | $6,490 |
| Prednisolone Acetate | 166 | $4,808 |
| Bromfenac Sodium | 17 | $3,502 |
| Loteprednol Etabonate | 17 | $2,665 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 26 | $2,183 |
| Brimonidine Tartrate | 28 | $2,176 |
| Ketorolac Tromethamine | 61 | $1,495 |
| Timolol Maleate | 142 | $1,462 |
| Fluorometholone | 19 | $1,169 |
| Difluprednate | 11 | $1,064 |
| Latanoprost | 140 | $938 |
| Dorzolamide Hcl | 49 | $866 |
| Acetazolamide | 16 | $757 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCombigan, Lumigan, Restasis | $310 | $21,68365 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 108 retina specialist providers in Texas.
Other retina specialist in San Antonio
- Moises ChicaSan Antonio$43K
- Sarah HolySan Antonio$18K
- Richard LaneSan Antonio$17K
- Duncan FriedmanSan Antonio$9K
- Thomas OeiSan Antonio$9K
- Timothy ClelandSan Antonio$6K
- Lina MaroufSan Antonio$4K
- Dianne BarrettSan Antonio$4K
- Abumere AkinwaleSan Antonio$3K
- Rushil RaoSan Antonio$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.